The rational design of suicide substrates of amine oxidases.

No abstract is available for this paper.

• Publication year

  1986

• Venue

  Biochemical Society Transactions

• Publication date

  1986-04-01

• Fields of study

  Medicine, Philosophy, Chemistry

• Identifiers
  DOI 10.1042/BST0140410PMID 3086155
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• (Z)-2-(2,4-Dichlorophenoxy)methyl-3-fluoroallylamine (MDL 72638): a clorgyline analogue with surprising selectivity for monoamine oxidase type B.

  1986cited by this paper
• An allylamine derivative (MDL 72145) with potent irreversible inhibitory actions on rat aorta semicarbazide‐sensitive amine oxidase

  1985cited by this paper
• Inhibition of Monoamine Oxidase Selectively in Brain Monoamine Nerves Using the Bioprecursor (E‐β‐Fluoromethylene‐m‐Tyrosine (MDL 72394), a Substrate for Aromatic L‐Amino Acid Decarboxylase

  1985cited by this paper
• Enzyme-activated irreversible inhibitors of monoamine oxidase: phenylallylamine structure-activity relationships.

  1985cited by this paper
• Amine oxidase activities in brown adipose tissue of the rat: identification of semicarbazide‐sensitive (clorgyline‐resistant) activity at the fat cell membrane

  1984cited by this paper
• Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

  1984cited by this paper
• (E)-2-(3,4-dimethoxyphenyl)-3-fluoroallylamine: a selective, enzyme-activated inhibitor of type B monoamine oxidase.

  1984cited by this paper
• MDL 72145, an Enzyme‐Activated Irreversible Inhibitor with Selectivity for Monoamine Oxidase Type B

  1984cited by this paper
• Cerebral decarboxylation of meta- and para-tyrosine.

  1983cited by this paper
• Amine oxidase in human blood vessels and non‐vascular smooth muscle

  1981cited by this paper
• Monoamine oxidase inhibitors. A review of antidepressant effectiveness.

  1979cited by this paper
• Inhibition of monoamine synthesis by irreversible blockade of aromatic aminoacid decarboxylase with alpha-monofluoromethyldopa.

  1979cited by this paper
• The action of plasma amine oxidase on beta-haloamines. Evidence for proton abstraction in the oxidative reaction.

  1975cited by this paper
• A kinetic evaluation of monoamine oxidase activity in rat liver mitochondrial outer membranes.

  1974cited by this paper
• 3-Bromoallylamine induced irreversible inhibition of monoamine oxidase.

  1973cited by this paper
• A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone.

  1973cited by this paper
• Some observations upon a new inhibitor of monoamine oxidase in brain tissue.

  1968cited by this paper
• HYPERTENSIVE CRISIS DUE TO MONOAMINE-OXIDASE INHIBITORS.

  1963cited by this paper

• On the practical aspects of characterising monoamine oxidase inhibition in vitro

  2018cites this paper
• Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins.

  2009cites this paper
• The Effects of Chronic Administration of Inhibitors of Flavin and Quinone Amine Oxidases on Imidazoline I1 Receptor Density in Rat Whole Brain

  2003cites this paper
• A study on the reactions of plant copper amine oxidase with C3 and C4 aliphatic diamines.

  2000cites this paper
• Developmental vasculotoxicity associated with inhibition of semicarbazide-sensitive amine oxidase.

  1999cites this paper
• PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

  1998cites this paper
• Effect of haloallylamines on polyamine oxidase activity and spermine levels in Ascaris suum

  1996cites this paper
• Active-site covalent modifications of quinoprotein amine oxidases from Aspergillus niger. Evidence for binding of the mechanism-based inhibitor, 1,4-diamino-2-butyne, to residue Lys356 involved in the catalytic cycle.

  1994cites this paper
• Biochemical and pharmacological evaluation of 2,4-difluorobenzyldimethylsilylmethanamine, a new highly selective inhibitor of monoamine oxidase-B.

  1994cites this paper
• Can our knowledge of monoamine oxidase (MAO) help in the design of better MAO inhibitors?

  1994cites this paper
• Haloallylamine inhibitors of MAO and SSAO and their therapeutic potential.

  1994cites this paper
• Medicinal Chemistry of Present and Future MAO-B Inhibitors

  1993cites this paper
• MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease.

  1993cites this paper
• The molecular pharmacology of L-deprenyl.

  1992cites this paper
• 1,4-Diamino-2-butyne as the mechanism-based pea diamine oxidase inhibitor.

  1992cites this paper
• The new generation of monoamine oxidase inhibitors.

  1992cites this paper
• 7 – MECHANISM-BASED ENZYME INHIBITORS AS AN APPROACH TO DRUG DESIGN

  1989cites this paper
• Interactions of monoamine oxidase with substrates and inhibitors

  1989cites this paper
• MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease

  1989cites this paper
• The Cyclopropyl Group in Studies of Enzyme Mechanism and Inhibition

  1988cites this paper
• Die Cyclopropylgruppe in Untersuchungen über Mechanismus und Hemmung von Enzymen

  1988cites this paper
• Enzyme-activated/mechanism-based inhibitors.

  1987cites this paper
• Inhibition of rat aorta semicarbazide-sensitive amine oxidase by 2-phenyl-3-haloallylamines and related compounds.

  1987cites this paper
• Monoamine Oxidase Enzymes

  1987cites this paper
• Overview of the present state of MAO inhibitors.

  1987cites this paper